Can an Antibody Allele Boost Your Alzheimer’s Risk By Giving Herpes an Edge?
Homozygous carriers of GM17—a common IgG1 variant the HSV-1 virus has evolved to evade—had quadruple the risk of developing AD. In a small Swedish cohort, that is.
ALL NEWS
5721 RESULTS
Sort By:
FDA Advisors Will Take up Aducanumab on November 6
The day-long advisory committee meeting will be broadcast live online. Prerecorded presentations are to be available November 4; the public can submit comments.
We Are What We Consume? Foods, Drugs Affect Amyloid, AD
A trend is afoot in Alzheimer disease research that is both potentially alarming and hopeful...
Virtual Meetings Try Out Different Formats
A recent genetics symposium drew positive reviews for its approach of following up prerecorded, on-demand talks with a live Q&A session.
Could Contaminated Scalpels Seed Amyloidosis?
A panel of experts concludes the evidence for this scary prospect is weak, but recommends neurosurgeons use separate neurosurgical instruments for young and old patients. The experts called for further studies.
CPTX—A Synaptic “Glue” Restores Memory in Alzheimer’s Model
The designer chimera stabilizes synapses in various mouse models of neurodegenerative disease.
Of Four Aβ Antibodies, Only Aducanumab Stems Tide of Toxic Oligomers
While one anti-Aβ antibody thwarts initial seeding of fibrils, and others keep fibrils from lengthening, aducanumab prevents oligomers forming on their surface. In vitro, that is.
First Primate Model of Familial AD: Marmosets with Presenilin Mutation
Three young monkeys missing exon 9 of presenilin 1 seem to have an elevated Aβ42/40 ratio. It remains to be seen if they will develop plaques and tangles as they age.
VCP Coding Mutation Causes a Tauopathy With Vacuoles
Carriers of a rare hypomorphic gene variant develop a frontotemporal dementia that features Alzheimer’s-like neurofibrillary tangles.
NIA Weighs in on Neurodegenerative Disease Transmissibility
Expert panel concludes there’s little risk based on current evidence.
Mysterious RNA Circles Crop up in Alzheimer’s Brain
The circular transcripts correlate with AD pathology and dementia severity, suggesting potential roles in pathogenesis or as biomarkers.
Parkinson’s Treatments Go After Genetic Targets
Researchers at AAT-AD/PD discussed investigational PD treatments that aim to modify disease by hitting genetic risk factors.
Antibody Against α-Synuclein Looks Safe In Phase 1
Treatments targeting the main pathological protein of Parkinson’s disease are moving toward the clinic, with two immunotherapies passing Phase 1 safety benchmarks.
Parsing How Alzheimer’s Genetic Risk Works Through Microglia
Scientists at AD/PD 2019 see a Goldilocks of microglial activation: Both too little and too much is bad in an injured brain. How could a therapy make it just right?
New ACE Variant Speeds Neurodegeneration in Alzheimer’s Mice
The R1279Q variant of angiotensin-converting enzyme associates with AD and causes neurodegeneration in mice. In a model of amyloidosis, it accelerates decline.
Current Filters
- Date Range : All x